Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD
Recruitment status was: Not yet recruiting
THis study aims to determine whether frequent dosing of intravitreal injections of Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a deleterious effect on the retina, studied by electrophysiologic testing.
This prospective, non-randomized clinical study will include patients assigned to intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as long as will be deemed necessary. Periodic electrophysiologic evaluation including Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests will be performed every 3 months.
Procedure: Electroretinography (ERG), Visual Evoked Potentials (VEP)
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Please refer to this study by its ClinicalTrials.gov identifier: NCT00533689
|Departent of Ophthalmlogy, Tel Aviv Sourasky Medical Center|
|Tel Aviv, Israel, 64239|
|Principal Investigator:||Michaella Goldstein, MD||Tel-Aviv Sourasky Medical Center|
|Study Director:||Anat Loewenstein, MD||Tel-Aviv Sourasky Medical Center|
|Study Chair:||Ido Perlman, PhD||Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel|